A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2019; you can also visit the original URL.
The file type is
Pharmacokinetic and safety profile of raltegravir and ribavirin, when dosed separately and together, in healthy volunteers
Journal of Antimicrobial Chemotherapy
Treatment of chronic hepatitis C virus (HCV) infection in HIV-1-co-infected individuals remains challenging due to numerous factors, including drug -drug interactions. The aim of this study was to assess the safety and pharmacokinetic (PK) profile of raltegravir and ribavirin when dosed separately and together. Methods: Fourteen healthy volunteers [mean (standard deviation) age 35 (10) years, 71% male] entered this phase 1 PK study and received single-dose ribavirin (800 mg) on day 1 (phase 1).doi:10.1093/jac/dkr093 pmid:21406434 fatcat:kyf5nj5ie5fuveffzi2y6f5uuy